ArticleThe journal of gene medicine2026
ATP6V0D2 Promotes Atherosclerosis-Associated Vascular Smooth Muscle Cell Dysfunction by Modulating Ferroptosis-Related Signaling.
Article in The journal of gene medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtherosclerosis (AS) underlies a substantial proportion of cardiovascular morbidity and mortality, yet the molecular events that drive vascular cell injury remain only partly resolved.
methodsWe first compared aortic transcriptomes from apolipoprotein E-deficient (ApoE-/-) mice maintained on control or high-fat diets. Candidate-gene effects were then examined in human vascular smooth muscle cells (HVSMCs) challenged with oxidized low-density lipoprotein (ox-LDL).
resultsThe aortic dataset contained 2832 differentially expressed genes (1800 increased and 1032 decreased). Of the five genes taken forward, ATP6V0D2 displayed a graded increase as the ox-LDL concentration rose. Network and enrichment results connected ATP6V0D2 to proton movement, acidification of intracellular organelles, and iron transport. Silencing ATP6V0D2 limited the ox-LDL-evoked accumulation of neutral lipid and restrained cell-cycle entry, motility, and invasion. At the molecular level, knockdown lowered acyl-CoA synthetase long-chain family member 4 (ACSL4) and recovered solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). It also raised glutathione (GSH) abundance and superoxide dismutase (SOD) activity while decreasing malondialdehyde (MDA), reactive oxygen species (ROS), mitochondrial contraction, and cristae damage. Ferrostatin-1 shifted the molecular, redox, and ultrastructural readouts in the same direction.
conclusionsThese data identify ATP6V0D2 as a contributor to the abnormal HVSMC phenotypes produced by ox-LDL. Its depletion appears to blunt this response, in part through attenuation of changes compatible with ferroptosis and warrants further evaluation as a mechanistic target for AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.